Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 948

Results For "MP"

9882 News Found

Kovai Medical Center & Hospital PAT at Rs 35.22 cr. for Q1FY22
News | August 13, 2021

Kovai Medical Center & Hospital PAT at Rs 35.22 cr. for Q1FY22

EPS at Rs 32.19

HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Healthcare | August 13, 2021

HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY

Substantial reduction in losses

Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
Drug Approval | August 12, 2021

Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness

A treatment to prevent extreme symptoms and cut hospitalisation

Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
Drug Approval | August 12, 2021

Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee

The company is eligible for 12 months exclusivity from launch

Natco Pharma PAT at Rs 75 crore for Q1FY22
News | August 12, 2021

Natco Pharma PAT at Rs 75 crore for Q1FY22

The company has strong product launches both in India and overseas

Indian pharma market grew by 13.7% in July 2021: Ind-Ra
News | August 12, 2021

Indian pharma market grew by 13.7% in July 2021: Ind-Ra

Demand normalisation post the second wave contributed to the steady growth

Aster DM Healthcare PAT at Rs 44.47 crores for Q1FY22
News | August 12, 2021

Aster DM Healthcare PAT at Rs 44.47 crores for Q1FY22

Income declines marginally

Global cell expansion market poised for huge growth
Biotech | August 12, 2021

Global cell expansion market poised for huge growth

Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
Drug Approval | August 12, 2021

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial

Low-cost flexible tactile sensors for robotics and biomedical applications developed
Drug Approval | August 12, 2021

Low-cost flexible tactile sensors for robotics and biomedical applications developed

The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery

Latest Stories

New support group targets delayed diagnosis of Vasculitis in India

Energy drinks emerging as hidden driver of liver damage in India’s youth, warn experts

Lupin subsidiary settles US antitrust case with Humana for $30 Million

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging